Figure 1B shows that the expression of cyclin and cyclin-dependent kinases (Cyclin D1, Cyclin E, CDK2, CDK4) and cancer stem cell master genes (CD133, OCT4, NANOG, and Sox2) in the GEM-treated group was significantly higher than that in the control group, which is consistent with our expectation. This evidence concerns the gene SOX2 and cancer.